VALN
Strong SellSinkerValneva SE · Healthcare · France · $610M · Avg Vol: $909K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT VALNEVA SE
Read
Valneva SE is a specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. The company's competitive moat is derived from its innovative vaccine platforms and a strong pipeline, including a leading candidate for Lyme disease and a Chikungunya vaccine, leveraging its expertise in viral vaccines. Valneva is a key player in the global vaccine development landscape, addressing public health challenges.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 415.1M | 176.6M | 194.9M | 200.7M | -21.5% | 164.1M | 173.5M | 325.6M | 27.4% |
| EPS | -2.85 | -1.68 | -0.18 | -1.56 | — | -2.08 | -1.30 | 1.37 | — |
| Shares | 138.4M | 138.8M | 162.4M | 173.4M | +25.3% | — | — | — | — |
| Debt | 175.1M | 239.9M | 248.5M | 238.1M | 10.8% | 241.3M | — | — | — |
| Equity | 252.6M | 147.4M | 208.3M | 122.0M | -21.5% | — | — | — | — |
| Op CF | -281.9M | -233.0M | -77.2M | -60.8M | — | -63.9M | — | — | — |
| Inv CF | -33.4M | -23.7M | 88.4M | -2.0M | — | — | — | — | — |
| Fin CF | 247.2M | 72.5M | 35.3M | -0.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VALN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VALN | Valneva SE(you) | $610M | 12 | Strong Sell |
| 0QAV.L | Nanobiotix S.A. | $627M | 5 | Strong Sell |
| DBVT | DBV Technologies S.A. | $851M | 8 | Strong Sell |
| IVA.PA | Inventiva S.A. | $1.1B | 8 | Strong Sell |
| CLLS | Cellectis S.A. | $342M | 6 | Strong Sell |
| MEDCL.PA | MedinCell S.A. | $1.0B | 21 | Sell |
| IPHA | Innate Pharma S.A. | $248M | 16 | Strong Sell |
| TNG.PA | Transgene SA | $259M | 18 | Strong Sell |
| GNFT.PA | Genfit S.A. | $835M | 36 | Hold |
| ALSEN.PA | Sensorion SA | $162M | 3 | Strong Sell |
Peer medians: ROE -32.6% · P/E 22.9x · Gross margin 73.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.